AZD4063
Phase 1Recruiting 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Dilated Cardiomyopathy
Conditions
Dilated Cardiomyopathy
Trial Timeline
Dec 1, 2025 → Nov 22, 2027
NCT ID
NCT07241104About AZD4063
AZD4063 is a phase 1 stage product being developed by AstraZeneca for Dilated Cardiomyopathy. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07241104. Target conditions include Dilated Cardiomyopathy.
What happened to similar drugs?
1 of 2 similar drugs in Dilated Cardiomyopathy were approved
Approved (1) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
6
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07241104 | Phase 1 | Recruiting |
Competing Products
10 competing products in Dilated Cardiomyopathy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Carvedilol + Metoprolol succinate + Metoprolol succinate + doxazosin | AstraZeneca | Approved | 43 |
| AZD0233 + AZD0233 Placebo | AstraZeneca | Phase 1 | 21 |
| ARRY-371797, p38 inhibitor, oral | Pfizer | Phase 2 | 35 |
| ARRY-371797 (PF-07265803) | Pfizer | Phase 3 | 32 |
| ARRY-371797, p38 inhibitor; oral | Pfizer | Phase 2 | 35 |
| danicamtiv | Bristol Myers Squibb | Phase 2 | 27 |
| Ixmyelocel-T | Vericel | Phase 2 | 29 |
| ixmyelocel-T | Vericel | Phase 2 | 29 |
| Ixmyelocel-T | Vericel | Phase 2 | 29 |
| talfirastide | Constant Therapeutics | Phase 2 | 21 |